NightHawk Biosciences announced its Scorpius BioManufacturing subsidiary (?Scorpius?) has commenced work on a contract that it was awarded by a leading university to develop and manufacture a novel biologic targeting substance use disorder, which includes drug, alcohol and opioid addiction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.107 USD | -33.12% | +39.32% | -75.70% |
May. 14 | Top Midday Decliners | MT |
May. 01 | Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-75.70% | 3.86M | |
+14.99% | 78.22B | |
+8.38% | 8.84B | |
-12.05% | 5.07B | |
+53.66% | 4.82B | |
+11.63% | 4.2B | |
-23.67% | 2.28B | |
+12.07% | 2.28B | |
-32.35% | 2.12B | |
+21.04% | 2.2B |
- Stock Market
- Equities
- SCPX Stock
- News Scorpius Holdings, Inc.
- Scorpius BioManufacturing Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement for A Leading National University